Dong-A ST Co., Ltd. (KRX:170900)

South Korea flag South Korea · Delayed Price · Currency is KRW
50,800
-800 (-1.55%)
At close: Jul 18, 2025, 3:30 PM KST
-26.50%
Market Cap465.49B
Revenue (ttm)724.59B
Net Income (ttm)-781.19M
Shares Out9.16M
EPS (ttm)-87.58
PE Ration/a
Forward PE22.98
Dividend686.27 (1.35%)
Ex-Dividend DateMar 13, 2025
Volume20,733
Average Volume21,620
Open51,900
Previous Close51,600
Day's Range50,300 - 51,900
52-Week Range40,900 - 79,118
Beta0.48
RSI59.25
Earnings DateJul 28, 2025

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation... [Read more]

Sector Healthcare
Founded 1932
Employees 1,687
Stock Exchange Korea Stock Exchange
Ticker Symbol 170900
Full Company Profile

Financial Performance

Financial Statements

News

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

– Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations SEOUL, South Korea — Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULD...

7 months ago - Financial Post

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration SEOUL, South Korea — Dong-A ST (President/CEO Jae-Hun Jung...

10 months ago - Financial Post

US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST's biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration Dong-A ST (President/CEO Jae-Hun Jung, KRX: 170900) announ...

10 months ago - Benzinga